Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States

IMPORTANCE: Immune checkpoint inhibitor combination therapy has recently become the standard of care for first-line treatment of metastatic nonsquamous non–small cell lung cancer. The implications of these first-line treatments are considerable, given the potential population of patients eligible to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Netw Open
Main Authors: Criss, Steven D., Mooradian, Meghan J., Watson, Tina R., Gainor, Justin F., Reynolds, Kerry L., Kong, Chung Yin
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6764123/
https://ncbi.nlm.nih.gov/pubmed/31553470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.11952
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados